


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



C-MER 希瑪

C-MER EYE CARE HOLDINGS LIMITED

希瑪眼科醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3309)

POSITIVE PROFIT ALERT

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of C-MER Eye Care Holdings Limited (the “**Company**” which together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Based on the financial information currently available, the Directors expect that the profit attributable to the equity holders of the Company for the year ended 31 December 2021 (“**FY2021**”) would be in the range of HK\$15.0 million to HK\$25.0 million, as compared with a loss of HK\$6.2 million for the year ended 31 December 2020 (“**FY2020**”). The turnaround in the Group’s profitability in FY2021 was primary due to a significant increase in the Group’s revenue by over 55% to over HK\$1.1 billion in FY2021 from HK\$699.5 million in FY2020; at the same time, an increase in the share of profit from an associate, which carries out medical laboratory services, also contributed to the Group’s profitability in FY2021. However, the effect of revenue increase to the Group’s profits was partially offset by losses incurred by the Group’s hospitals and eye centres in their early investment stages, including the new eye hospital in Huizhou (which commenced business operations in March 2021), the eye hospital in Zhuhai (which commenced business operations in December 2020), and the new eye centre in Fuzhou (which commenced business operations in November 2021).

As the Company is still in the process of finalising the results for FY2021, the information contained in this announcement is based on the management's preliminary review on the management accounts of the Group and current information available to the Board and has not been audited and confirmed by the Company's auditors or the audit committee of the Board. Shareholders and potential investors of the Company are advised to read carefully the annual results announcement of the Company for FY2021 which is expected to be published by the end of March 2022.

Shareholders and prospective investors of the Company are advised to exercise caution when dealings in the shares of the Company.

By order of the Board
C-MER Eye Care Holdings Limited
Dr. LAM Shun Chiu Dennis JP
Chairman, Chief Executive Officer and Executive Director

Hong Kong, 14 March 2022

As of the date of this announcement, the Board comprises four executive Directors, namely Dr. LAM Shun Chiu Dennis, Ms. LI Xiaoting, Dr. LEE Yau Wing Vincent and Mr. LI Chunshan and six independent non-executive Directors, namely, Dr. AU YEUNG Rex Pak-kuen, Dr. LI Kwok Tung Donald, Mr. MA Andrew Chiu Cheung, Mr. CHAN Chi Leong, Ms. BENTLEY Annie Liang, and Mr. IP Shu Kwan Stephen.